TMCI - NASDAQ
Treace Medical Concepts, Inc.
$3.40
-5.6%Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.
At a Glance
Live SnapshotTreace Medical Concepts, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Treace Medical Concepts, Inc. Income Statement
TMCI • NASDAQ
| Treace Medical Concepts, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
212.7M | 209.4M | 187.1M | 141.8M | 94.4M | 57.4M | 39.4M | |
GROSS PROFIT | |||||||
(42.9M) | (41.1M) | (35.2M) | (27.5M) | (16.9M) | (12.5M) | (7.6M) | |
169.8M | 168.3M | 151.9M | 114.3M | 77.5M | 44.9M | 31.8M | |
OPERATING INCOME | |||||||
(223.9M) | (224M) | (203.4M) | (149.2M) | (94M) | (44M) | (35.3M) | |
(203.6M) | (203.4M) | (187.9M) | (137.6M) | (83.8M) | (38.2M) | (30.3M) | |
(20.3M) | (20.6M) | (15.4M) | (13.6M) | (10.2M) | (5.8M) | (5.1M) | |
-54.2M | -55.7M | -51.4M | -34.8M | -16.5M | 855K | -3.5M | |
PRE-TAX INCOME | |||||||
(5.3M) | (5.3M) | (5.2M) | (4.4M) | (4.1M) | (4.5M) | (841K) | |
-2.5M | -379K | 1.6M | -3.1M | -4M | -4.5M | -730K | |
(0.0) | (0.0) | (0.0) | -2M | (0.0) | (0.0) | (0.0) | |
-4.8M | -55K | 1.9M | -8M | -4M | -4.5M | -730K | |
-59M | -55.7M | -49.5M | -42.8M | -20.6M | -3.7M | -4.3M | |
NET INCOME | |||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (841K) | |
-59M | -55.7M | -49.5M | -42.8M | -20.6M | -3.7M | -4.3M |
SEC Filings
TMCI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 19, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 08, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 06, 2026 | April 03, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 27, 2026 | February 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 13, 2026 | January 13, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 16, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your TMCI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.